Clinical efficacy and adverse effects of cisapride in treating gastrointestinal motility disorders

Cisapride is an efficient prokinetic agent that plays a significant role in veterinary medicine, treating gastrointestinal (GI) motility disorders in various species such as dogs, cats, small mammals, chickens, reptiles, and rabbits. Its efficacy is especially significant for conditions like constipation, gastroesophageal reflux, megacolon, and megaoesophagus. While adverse effects are more frequently reported in cats, particularly at high doses—where they may experience diarrhea, vomiting, and, in rare instances, excessive salivation—it is important to note that animals with pre-existing cardiac conditions should be closely monitored with regular electrocardiograms (ECGs) during treatment. The aim of this study is to highlight the clinical applications of Cisapride as a resultful and reliable therapeutic option. For supporting the statement, we present three cases from our Veterinary Teaching Hospital involving cats suffering from constipation: two were treated with Cisapride syrup (1 mg/ml), and one received Cisapride as transdermal cream (1 mg/0,1ml) in conjunction with Lactulose Oral suspension. The cases achieved successful therapeutic outcomes, underscoring the potential of Cisapride as a valuable tool in veterinary care. In addition, we conducted an online survey among veterinary professionals to gather other insights into the clinical utilization, side effects, and outcomes associated with Cisapride across a range of species. The survey revealed that an overwhelming 81.8% of respondents do not incorporate Cisapride into their routine practices, while only 18.2% have utilized it in managing megacolon in cats. This research underscores the need for increased awareness and consideration of Cisapride in veterinary practices to enhance our ability to effectively manage GI motility disorders.